These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31420358)

  • 21. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
    Armand P; Chen YB; Redd RA; Joyce RM; Bsat J; Jeter E; Merryman RW; Coleman KC; Dahi PB; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Patel SS; Ritz J; Rodig SJ; Shipp MA; Herrera AF
    Blood; 2019 Jul; 134(1):22-29. PubMed ID: 30952672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
    Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.
    Mei Q; Zhang W; Liu Y; Yang Q; Rasko JEJ; Nie J; Liu J; Li X; Dong L; Chen M; Zhang Y; Shi L; Wu H; Han W
    Clin Cancer Res; 2020 Sep; 26(17):4521-4530. PubMed ID: 32499235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Experience of PD-1 Inhibitors for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Retrospective Analysis of Patients in China.
    Yu W; Geng M; Hao J; Yan Z; Mi JQ
    Acta Haematol; 2023; 146(4):307-315. PubMed ID: 37023729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Van Den Neste E; André M; Gastinne T; Stamatoullas A; Haioun C; Belhabri A; Reman O; Casasnovas O; Ghesquieres H; Verhoef G; Claessen MJ; Poirel HA; Copin MC; Dubois R; Vandenberghe P; Stoian IA; Cottereau AS; Bailly S; Knoops L; Morschhauser F
    Haematologica; 2018 May; 103(5):840-848. PubMed ID: 29351986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.
    Morschhauser F; Marlton P; Vitolo U; Lindén O; Seymour JF; Crump M; Coiffier B; Foà R; Wassner E; Burger HU; Brennan B; Mendila M
    Ann Oncol; 2010 Sep; 21(9):1870-1876. PubMed ID: 20157180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
    Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
    Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.
    Liu Y; Song Y; Zuo S; Zhang X; Liu H; Wang J; Wang J; Tang Y; Zheng W; Ying Z; Ping L; Zhang C; Wu M; Zhu J; Xie Y
    Front Immunol; 2023; 14():1128172. PubMed ID: 37081867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
    Merryman RW; Castagna L; Giordano L; Ho VT; Corradini P; Guidetti A; Casadei B; Bond DA; Jaglowski S; Spinner MA; Arai S; Lowsky R; Shah GL; Perales MA; De Colella JMS; Blaise D; Herrera AF; Shouse G; Spilleboudt C; Ansell SM; Nieto Y; Badar T; Hamadani M; Feldman TA; Dahncke L; Singh AK; McGuirk JP; Nishihori T; Chavez J; Serritella AV; Kline J; Mohty M; Dulery R; Stamatoulas A; Houot R; Manson G; Moles-Moreau MP; Orvain C; Bouabdallah K; Modi D; Ramchandren R; Lekakis L; Beitinjaneh A; Frigault MJ; Chen YB; Lynch RC; Smith SD; Rao U; Byrne M; Romancik JT; Cohen JB; Nathan S; Phillips T; Joyce RM; Rahimian M; Bashey A; Ballard HJ; Svoboda J; Torri V; Sollini M; De Philippis C; Magagnoli M; Santoro A; Armand P; Zinzani PL; Carlo-Stella C
    Leukemia; 2021 Sep; 35(9):2672-2683. PubMed ID: 33658659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
    Shan DD; Liu HM; Liu W; Huang WY; Lyu R; Deng SH; Yi SH; An G; Xu Y; Sui WW; Wang TY; Fu MW; Zhao YZ; Qiu LG; Zou DH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):555-560. PubMed ID: 37749034
    [No Abstract]   [Full Text] [Related]  

  • 35. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
    Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Zhao X; Wang D; Zhang P; Wang Y; Wang L; Liu T; Zhang Y; Shen Z; Huang J; Zhu J
    Clin Cancer Res; 2022 Mar; 28(6):1147-1156. PubMed ID: 34716199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
    Geoerger B; Zwaan CM; Marshall LV; Michon J; Bourdeaut F; Casanova M; Corradini N; Rossato G; Farid-Kapadia M; Shemesh CS; Hutchinson KE; Donaldson F; Liao M; Caron H; Trippett T
    Lancet Oncol; 2020 Jan; 21(1):134-144. PubMed ID: 31780255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.
    Shi Y; Cai Q; Jiang Y; Huang G; Bi M; Wang B; Zhou Y; Wang G; Ying H; Tao Z; Shi C; Guo Q; Gao C
    Clin Cancer Res; 2020 Dec; 26(24):6445-6452. PubMed ID: 33046518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
    Mei M; Chen L; Godfrey J; Song J; Egelston C; Puverel S; Budde LE; Armenian S; Nikolaenko L; Nwangwu M; Guo W; Gao L; Lee P; Chen R; Daniels S; Kennedy N; Peters L; Zain J; Rosen S; Forman S; Popplewell L; Kwak L; Herrera AF
    Blood; 2023 Oct; 142(16):1359-1370. PubMed ID: 37339586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
    Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Zeng S; Zhang Q; Hu J; Zhou H; Xiong Y; Liu P
    Lancet Haematol; 2019 Jan; 6(1):e12-e19. PubMed ID: 30612710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.